Eupraxia Pharmaceuticals (EPRX) Income Statement (2022 - 2025)
Annual Income Statement report data from Dec 31, 2022 to Dec 31, 2025 for Eupraxia Pharmaceuticals (EPRX).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
Operating Expenses | ||||
Research And Development | 21M (+32.65%) | 16M (-21.02%) | 20M (+49.38%) | 14M |
Selling General And Administrative | 17M (+56.59%) | 11M (+45.99%) | 7.48M (+87.47%) | 3.99M |
Operating Expenses | 38M (+42.33%) | 27M (-3.05%) | 28M (+58.06%) | 18M |
Depreciation And Amortization | 240K (+41.18%) | 170K (+6.25%) | 160K (+6.67%) | 150K |
Operating Income | ||||
Ebit | -38.56M (+54.86%) | -24.90M (-7.81%) | -27.01M (+54.25%) | -17.51M |
EBITDA | -38.32M (+54.95%) | -24.73M (-7.93%) | -26.86M (+54.72%) | -17.36M |
Other Income / Expenses | ||||
Interest Income | 1.41M (+21.55%) | 1.16M (+34.88%) | 860K (+100.00%) | 430K |
Interest Expense | - | 600K (-48.72%) | 1.17M (+19.39%) | 980K |
Net Interest Income | 1.41M (+151.79%) | 560K | -310.00K (-43.64%) | -550.00K |
Other Non Operating Income | -150.00K | 1.26M | -1.08M (-21.17%) | -1.37M |
Net Income | ||||
Income Before Tax | -38.59M (+49.92%) | -25.74M (-11.03%) | -28.93M (+52.34%) | -18.99M |
Income Tax Expense | 20K | - | 40K | - |
Net Income From Continuing Operations | -38.58M (+51.29%) | -25.50M (-9.64%) | -28.22M (+52.62%) | -18.49M |
Net Income | -38.58M (+51.29%) | -25.50M (-9.64%) | -28.22M (+52.62%) | -18.49M |
Comprehensive Income Net Of Tax | -36.49M (+34.15%) | -27.20M (-5.85%) | -28.89M (+42.53%) | -20.27M |